에 대한 최신 뉴스 Natera (NASDAQ:NTRA) 주식

Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

News

Movers

AXON

AZPN

FTNT

KVUE

MSFT

UBER

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 쇼피파이(NYSE:SHOP)는 강력한 실적 보고서와 2024년 3분기의 낙관적 전망에 따라 주가가 41.15% 상승했다. 몇몇 분석가들은 주식의 목표 주가를 수정했다.

쇼피파이 및 팔란티어는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 4일-8월 10일)

Natera Inc

Billionaire investor Stanley Druckenmiller's family office Duquesne has offloaded two of Wall Street's hottest AI stocks – Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), according to a recent 13F filing.
What Happened: Druckenmiller&#8217;s Duquesne Family Office sold all of its Nvidia shares and significantly reduced its Palantir holdings by 95% during the third quarter.
This comes after Nvidia and Palantir have been on a tear this year. While the Nvidia stock surged nearly 190% in 2024 so far, Palantir shares have gained over 386% to date.
While it's not clear why Duquesne has offloaded these two red-hot AI stocks, profit booking could be one of the motives.
Nvidia and Palantir's relatively rich valuations could also have contributed to Duquesne paring its holdings – while Nvidia's trailing 12 months (TTM) price-to-earnings (PE) ratio stands at 55.21, Palantir's stands at 403.45.
Meanwhile, Druckenmiller is increasing his stake in Teva Pharmaceutical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), a company that has seen its shares rise by 112% this year.
Teva&#8217;s strategic shift towards brand-name therapies and its resolution of opioid litigation as key factors contributing to its recent success.
Druckenmiller&#8217;s fund added 1,427,950 shares of Teva during the September-ended quarter, signaling confidence in the pharmaceutical company&#8217;s turnaround and growth potential.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42545656/bitcoin-is-no-manhattan-real-estate-peter-schiff-challenges-microstrategys-micheal-saylor-btc-doesnt-generate-any-income" target="_blank" rel="noreferrer noopener">Bitcoin Is No Manhattan Real Estate, Peter Schiff Challenges MicroStrategy's Michael Saylor: ‘BTC Doesn't Generate Any Income'</a>
Why It Matters:&nbsp;Druckenmiller, a protégé of&nbsp;George Soros, is renowned for his macroeconomic investment strategy, often making significant bets on industry trends rather than individual companies.
His recent decision to pivot from AI to pharmaceuticals marks a notable shift in his investment focus. Earlier this year, Druckenmiller <a href="https://www.benzinga.com/24/12/42659876/stanley-druckenmiller-pours-funds-into-1-trillion-company-already-trading-up-100">increased his stake</a> in&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), a semiconductor giant, demonstrating his interest in high-growth sectors.
In February, <a href="https://www.benzinga.com/markets/equities/24/02/37175336/billionaire-investor-stanley-druckenmillers-firm-dumps-alphabet-amazon-boosts-investments-in-ai-">Druckenmiller&#8217;s firm divested from</a>&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) while <a href="https://www.benzinga.com/markets/equities/24/02/37175336/billionaire-investor-stanley-druckenmillers-firm-dumps-alphabet-amazon-boosts-investments-in-ai-">bolstering investments in AI leaders</a> like&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and&nbsp;Nvidia.
Despite his bullish stance on AI, Druckenmiller&#8217;s recent actions suggest a <a href="https://www.benzinga.com/general/health-care/24/12/42627207/stanley-druckenmillers-top-holding-has-outperformed-its-sector-by-252">strategic realignment towards</a> the healthcare sector, particularly in companies like&nbsp;Natera Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), which has outperformed its sector significantly.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42495782/crypto-market-predicted-to-surge-to-all-time-highs-by-late-2025-but-a-30-drop-in-bitcoin-prices-could-come-first" target="_blank" rel="noreferrer noopener">Crypto Market Predicted To Surge To All-Time Highs By Late 2025, But A 30% Drop In Bitcoin Prices Could Come First</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

Equities

Markets

General

AMZN

AVGO

GOOG

GOOGL

NVDA

TEVA

Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next

Billionaire Stanley Druckenmiller, a former confidant of George Soros and the founder of Duquesne Capital, built his career off making <a href="https://www.benzinga.com/general/24/03/37598371/stanley-druckenmillers-secret-sauce-the-two-stocks-dominating-a-quarter-of-his-three-billion-dollar">large, measured bets</a>. His latest large wager has paid off.
The famed investor has steadily increased his stake in Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a clinical genetic testing company, since the third quarter of 2022, according to quarterly 13F filings. Druckenmiller owned 414,955 shares in 2022&#8217;s third quarter, 893,030 shares in 2023 and 3,566,850 shares in 2024.
Druckenmiller&#8217;s position now exceeds $575 million, nearly 3% of the Austin, Texas-based company&#8217;s market capitalization and 15% of Duquesne Capital&#8217;s portfolio.
Since Duquesne Capital revealed its stake in a 13F filing, its stock has traded up 268%. Meanwhile, the healthcare industry as a whole, as measured by the iShares US Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), has risen a touch over 16%. Thus, Druckenmiller&#8217;s gamble has outperformed its sector by over 250%.
Also Read: <a href="https://www.benzinga.com/markets/equities/24/12/42624528/government-shutdown-threat-stocks-wobble-holiday-travel-and-paychecks-could-face-delays-what-you-need-to-know">Government Shutdown Threat: Holiday Travel, Paychecks Could Face Delays If No Deal Reached</a>
Natera specializes in genetic testing and diagnostics to improve healthcare outcomes. The company develops and markets tests that analyze DNA to provide insights into hereditary conditions, reproductive health, organ transplant health, and oncology. 
Natera's flagship products include non-invasive prenatal tests (NIPTs) like Panorama, which screens for chromosomal abnormalities in a fetus, and Horizon, a carrier screening test for hereditary conditions.
In recent years, Natera has expanded its focus to oncology and organ transplant monitoring. In oncology, the company's Signatera test detects minimal residual disease (MRD) in cancer patients, helping to guide treatment decisions and monitor for recurrence with precision.
In the transplant space, the Prospera test assesses organ health by measuring donor-derived cell-free DNA, providing early indications of transplant rejection.
The company has beaten earnings and revenue expectations over the past four quarters. Revenue has increased from $625 million in 2021 to $1.5 billion over the past twelve months, while margins have also expanded. The company has posted a positive operating cash flow since March.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Health Care

Hedge Funds

Trading Ideas

iShares Trust Dow Jones US Healthcare Sector Index Fund

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Investors with significant funds have taken a bullish position in Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in NTRA usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 12 options transactions for Natera. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 91% being bullish and 0% bearish. Of all the options we discovered, 11 are puts, valued at $1,304,670, and there was a single call, worth $28,000.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $160.0 for Natera over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Natera options trades today is 137.5 with a total volume of 14,736.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Natera's big money trades within a strike price range of $160.0 to $160.0 over the last 30 days.
<h3>Natera Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734119344_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$160.00</td>
<td>$380.0K</td>
<td align="right">134</td>
<td>1.2K</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.8</td>
<td>$7.3</td>
<td>$7.3</td>
<td>$160.00</td>
<td>$219.0K</td>
<td align="right">134</td>
<td>305</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.3</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$160.00</td>
<td>$115.2K</td>
<td align="right">134</td>
<td>1.5K</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.2</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$160.00</td>
<td>$112.5K</td>
<td align="right">134</td>
<td>605</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.6</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$160.00</td>
<td>$89.7K</td>
<td align="right">134</td>
<td>1.9K</td>
</tr>
</tbody>
</table>

<h3>About Natera</h3>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Current Position of Natera</h3>
<ul>
<li>Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 75 days.</li>
</ul>
<h3>Expert Opinions on Natera</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $192.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Natera, maintaining a target price of $200. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Natera, maintaining a target price of $200. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Natera, targeting a price of $176. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Natera options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Market Whales and Their Recent Bets on NTRA Options

JP Morgan analyst Julia Qin maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $160 to $200.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Natera, Raises Price Target to $200

Natera shares are trading higher. The stock may be moving on continued strength after the company announced yesterday the enrollment of its first patients in SAGITTARIUS, a randomized Phase III clinical trial for colon cancer.

SAGITTARIUS is Natera's first interventional trial using SignateraTM to select patients for targeted therapy in early-stage colon cancer
Approximately 700-900 patients expected to be enrolled across more than 20 sites
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54165644&amp;newsitemid=20241212128799&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=0d1cd45cd5947a2b3f7b0540e214d52b">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinical trial designed to evaluate the use of Signatera to guide personalized adjuvant treatment strategies for patients with colon cancer.
The study aims to enroll approximately 700-900 stage III and high-risk stage II colon cancer patients following surgical resection.
<ul>
<li>Signatera-positive patients will be randomized to receive either genotype-guided therapy tailored to their individual tumor mutational profile or six months of standard chemotherapy. The trial's investigational arm will explore the potential of administering immunotherapy or targeted agents approved for metastatic colon cancer earlier in the disease course to increase the proportion of patients cured with adjuvant therapy. This genomically-driven approach will focus on mismatch repair status, POLE, RAS/RAF mutation status, and HER2 amplification status.</li>
<li>For Signatera-negative patients, the trial will compare physician choice treatments with options for de-escalation to observation or single-agent capecitabine for six months.</li>
</ul>
SAGITTARIUS includes collaborations with 9 partners in 5 countries in Europe, and a network of 26 clinical centers in Italy, Spain, and Germany.

Biotech

Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites

Natera Announces Launch Of iPRS For Breast Cancer Risk Assessment

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has fallen 6.33% since its last report. The company recently reported that it has 3.74 million shares sold short, which is 2.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733161520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Natera's Recent Short Interest

Test demonstrated high performance metrics in largest study of its kind in the US with sensitivity of 100% and specificity of 99.3%
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54159522&amp;newsitemid=20241202602532&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=6047985f82cc3e83d1744b37218ceaea">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics &amp; Gynecology (also known as The Green Journal) <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.lww.com%2Fgreenjournal%2Fpages%2Farticleviewer.aspx%3Fyear%3D9900%26issue%3D00000%26article%3D01185%26type%3DFulltext&amp;esheet=54159522&amp;newsitemid=20241202602532&amp;lan=en-US&amp;anchor=published+the+Company%26%238217%3Bs+clinical+validation+study&amp;index=2&amp;md5=671b0289a479c1f3b2bdd02c5348fa1a">published the Company's clinical validation study</a> on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT).
Natera's study is the largest clinical validation of a fetal RhD test performed in the United States to date, with fetal RhD status confirmed via newborn serology in 655 RhD-negative pregnant patients. The study provides compelling scientific evidence on the ability of Natera's Fetal RhD NIPT to identify fetal RhD status, and demonstrates its potential to assist patients and clinicians in the prevention and management of RhD alloimmunization. In addition, Natera's next generation sequencing (NGS)-based Fetal RhD test can identify RHD pseudogene and other hybrid variants that are more commonly occurring in people of non-European ancestries.
Key highlights of the study include:
<ul>
<li>356/356 fetuses were correctly identified as fetal RhD positive (sensitivity: 100% [95% CI: 98.9-100.0]).</li>
<li>Of the 297 RhD-negative fetuses, 295 were correctly identified as RhD-negative (specificity of 99.3% [95% CI: 97.6-99.8]).</li>
<li>Positive predictive value for the test was 99.4% and negative predictive value was &gt;99.9%.</li>
<li>The study included a representative mix of race and ethnicities in the RhD-negative U.S. population.</li>
</ul>
RhD alloimmunization, which can lead to hemolytic disease of the fetus and newborn, can occur when an RhD-negative patient carries an RhD-positive fetus. Historically, this risk is well managed by giving Rho(D) immune globulin therapy (RhIg). However, approximately 40% of patients with an RhD-negative fetus receive this medication unnecessarily. This is particularly important as recent nationwide shortages of RhIg have created an even greater need for testing that allows providers to both prevent alloimmunization and conserve supplies of RhIg, consistent with recent <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.acog.org%2Fclinical%2Fclinical-guidance%2Fpractice-advisory%2Farticles%2F2024%2F03%2Frhod-immune-globulin-shortages&amp;esheet=54159522&amp;newsitemid=20241202602532&amp;lan=en-US&amp;anchor=guidance&amp;index=3&amp;md5=2a0dd926c7ec4a85c18a055b5118c957">guidance</a> from the American College of Obstetricians and Gynecologists (ACOG) supporting cfDNA screening for fetal RhD testing.

Natera Announces That Obstetrics & Gynecology Published The Company's Clinical Validation Study On Its Cell-Free DNA Fetal RhD Noninvasive Prenatal Test

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54158763&amp;newsitemid=20241127854263&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=a543378fab0fd18a5dfd1253a03d055c">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage applies to SLT patients in the surveillance setting.
SLT patients make up ~20% of all U.S. lung transplants1. These patients are at an increased risk for acute rejection and also for complications from invasive procedures like biopsies due to common factors including advanced age, frailty, comorbidities, and functional dependency on a single lung. This creates an increased need for non-invasive monitoring solutions, like Prospera Lung.
The performance of Prospera Lung for SLT patients was published earlier this year from the Single Lung Allograft Monitoring (a.k.a. SLAM) study, the largest study of commercial donor-derived cell free DNA (dd-cfDNA) tests in SLT to-date. The data demonstrated excellent performance for Prospera in distinguishing rejection, infection, and chronic lung allograft disease (CLAD) from stable patients with an AUC-ROC of 0.85. These results are on par with Prospera's outstanding performance in double-lung transplants, and can ultimately provide confidence to rule out rejection, highlighted by a sensitivity of 77.8%, specificity of 84.6%, and a negative predictive value (NPV) of 96.8%.

Natera Announces Its Prospera Lung Test Has Met Coverage Requirements From The Centers For Medicare & Medicaid Services' Molecular Diagnostics Services Program For Single Lung Transplant Recipients; This Coverage Applies To SLT Patients In The Surveillance Setting.

Reported Earlier, Natera To Present Latest Data On Signatera At 2024 San Antonio Breast Cancer Symposium

The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal – Guardant Health's tissue-free minimal residual disease (MRD) test for early-stage colorectal cancer (CRC) – in favor of Signatera&#x2122;, Natera's competing product.&nbsp;

Legal

Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54158126&amp;newsitemid=20241125988408&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=2d21eac203e9f33cadb6a9b245380da5">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today issued the following statement:
In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant's Reveal test. Today, a jury issued a decision in Guardant's favor. We disagree with this decision and will ask the Court to overturn it.
The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test. This case had nothing to do with the validity or utility of Signatera, and certain key pieces of evidence supporting Natera's case were not included in this trial.
In the years that have passed since these events, Signatera has become the most widely used MRD test in the U.S., extensively validated with published evidence in more than 100 peer-reviewed papers across multiple cancer types and indications.

Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"

13 analysts have shared their evaluations of Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $158.69, a high estimate of $200.00, and a low estimate of $135.00. Marking an increase of 16.03%, the current average surpasses the previous average price target of $136.77. 
<img src="https://www.benzinga.com/files/images/story/2024/1731952822_0_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Natera among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Natera compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Natera's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Natera's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Natera analyst ratings.</a>
<h2>Discovering Natera: A Closer Look</h2>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Natera: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Natera's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 63.9% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Natera's net margin is impressive, surpassing industry averages. With a net margin of -7.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Natera's ROE excels beyond industry benchmarks, reaching -3.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Natera's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.03%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Natera's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Natera's Future

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $150 to $200.

Piper Sandler Maintains Overweight on Natera, Raises Price Target to $200

Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $132 to $176.

Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $176

<h3>Gainers</h3>
<ul>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares rose 22.7% to $2.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $331.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 19.74% to $2.46. The market value of their outstanding shares is at $31.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 18.48% to $2.5. The market value of their outstanding shares is at $29.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) shares rose 16.66% to $157.64. The company's market cap stands at $19.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 15.62% to $0.78. The market value of their outstanding shares is at $11.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock increased by 12.61% to $8.66. The company's market cap stands at $286.3 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares decreased by 85.6% to $0.39 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 72.24% to $0.44. The market value of their outstanding shares is at $2.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock fell 23.4% to $0.05. The company's market cap stands at $2.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined by 20.03% to $0.21. The market value of their outstanding shares is at $32.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares declined by 20.0% to $2.6. The company's market cap stands at $22.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 17.6% to $0.51. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

CLDI

ENSC

GCTK

GOVX

KAPA

LXEO

MRSN

SYRS

VRPX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) reported better-than-expected third-quarter financial results and issued FY24 revenue guidance <a href="https://www.benzinga.com/quote/NTRA/earnings">above estimates on Tuesday</a>.
Natera reported a quarterly loss of 26 cents per share, which beat the analyst consensus estimate of a loss of 58 cents per share . The company reported quarterly sales of $439.800 million which beat the analyst consensus estimate of $361.450 million.
&#8220;Our strong performance in the third quarter reflects our unwavering dedication to the patients we serve and the passion of our employees in each of our business areas,&#8221; said Steve Chapman, chief executive officer of Natera. &#8220;We grew volumes, revenue, gross margin, and cash flow in what continues to be a transformational year for Natera.&#8221;
Natera said it sees FY24 revenue of $1.61 billion to $1.64 billion, versus market estimates of $1.518 billion.
Natera shares jumped 22.3% to trade at $165.31 on Wednesday.
Several analysts made changes to their price targets for Natera following the release of quarterly results.
<ul>
<li>Baird analyst Catherine Ramsey maintained Natera with an Outperform and raised the price target from $120 to $160.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6013eddd879cba0001e6f199/kyle-mikson">Canaccord Genuity analyst Kyle Mikson </a>maintained the stock with a Buy and raised the price target from $150 to $165.</li>
<li>JP Morgan analyst Julia Qin maintained Natera with an Overweight and raised the price target from $135 to $160.</li>
<li>Craig-Hallum analyst Alexander Nowak maintained the stock with a Buy and increased the price target from $121 to $157.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e5d05312fc7510001ab2cc4/dan-brennan">TD Cowen analyst Dan Brennan </a>maintained Natera with a Buy and boosted the price target from $155 to $175.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41939161/how-to-earn-500-a-month-from-helmerich-payne-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Helmerich &amp; Payne Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Natera Analysts Increase Their Forecasts Following Upbeat Results

TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $155 to $175.

TD Cowen Maintains Buy on Natera, Raises Price Target to $175

Wall Street saw a modest rebound on Wednesday, spurred by an in-line inflation report that reinforced expectations for a December rate cut. The U.S. dollar continued to gain strength, buoyed by potential tariff tailwinds under <a href="https://www.benzinga.com/topic/donald-trump">the new Trump administration.</a>
Bitcoin again captured headlines as it surged past $93,000, lifting its market capitalization to $1.8 trillion and fueling a wave of enthusiasm across crypto markets, with Dogecoin up over 12%.
The Consumer Price Index met expectations in October, with the annual headline rate increasing to 2.6% and the core <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41938762/october-inflation-rate-rises-to-2-6-as-expected-december-interest-rate-cut-remains-uncertain">rate steady at 3.3%. </a>
The report alleviated concerns over a potential rate pause in December, driving market odds for a 25-basis-point cut from 58% to 82%, as per the CME FedWatch tool. Treasury yields eased slightly in response to the report.
By midday in New York, all major U.S. equity indices were in slightly positive territory, although with the tech-heavy Nasdaq 100 underperforming. Leading sectors included consumer discretionary and real estate, while utilities and health care lagged.
In political developments, U.S. Sen. John Thune (R-SD) was elected as the new majority leader in a secret ballot.
The U.S. dollar, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), hit its highest level since November 2023, marking a fresh one-year high.
Gold dipped 0.6%, on track for a fourth consecutive loss.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,084.11</td>
<td>0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,401.00</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,002.13</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,073.91</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.3% to $598.42.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.4% to $440.97.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) flattened at $513.06.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.3% higher to $238.1.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1%. The&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.3%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) rallied over 18% after the company announced a joint venture launch with Volkswagen valued at&nbsp;up to $5.8 billion.</li>
<li>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) rose 6% after Berenberg raised the stock price target from $81 to $102.</li>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) fell 2.4% after the company announced a 4% cut to its global workforce.</li>
</ul>
Stocks reacting to earnings report were: 
<ul>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), up 12%</li>
<li>Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), down 1.2%</li>
<li>Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), up 6.5%</li>
<li>Natera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), up 22%,</li>
<li>CAVA Group Inc., up 6.5%</li>
<li>CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>), down 0.3%</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>), down 6%</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/41940984/disney-bulls-await-earnings-for-streaming-growth-bob-iger-successor-clues">Disney Bulls Await Earnings For Streaming Growth, Bob Iger Successor Clues</a></li>
</ul>
Photo via Shutterstock.

Econ #s

Federal Reserve

CYBR

SPDR Dow Jones Industrial Average ETF Trust

FLUT

LOAR

RIVN

SPOT

PowerShares DB US Dollar Index Bullish Fund

Select Sector SPDR-Consumer Discretionary

Stocks Edge Higher, Dollar Hits 1-Year Peak, Bitcoin Soars To $93,000: What's Driving Markets Wednesday?

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2024 Update

Natera gets Medicare coverage for Prospera for single lung transplants

The latest announcement is out from Natera ( ($NTRA) ). Natera, Inc. has updated its employment terms with Executive Chairman Matthew Rabinowitz, h...

Natera Aligns Executive Chairman's Pay with Performance

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncolo...

Natera enrolls 1st patients in SAGITTARIUS clinical trial in colon cancer

JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. Th...

Natera price target raised to $200 from $160 at JPMorgan

Pioneer Select Mid Cap Growth Fund Q3 2024 Performance And Market Commentary

American Century Small Cap Growth Fund Q3 2024 Commentary

Alger Weatherbie Specialized Growth Fund Q3 2024 Commentary

Alger Dynamic Opportunities Fund Q3 2024 Commentary

FNX: A 'Value Or Growth' Mid-Cap ETF

AAPL

ADBE

ADMA

AFRM

ANET

ASND

AVDX

AZEK

BBMC

BOOT

CGJTF

COHR

CPNG

CRESY

CRWD

CWST

DAKT

DDOG

DUOL

DXCM

EXEEL

EXEEW

EXEEZ

FBIN

FDIS

FLEX

FLQM

GGAL

GRPM

HIMS

HLNE

ITGR

JHMM

MELI

MSCI

MSGE

NWSA

NWSAL

OLLI

OPCH

PANW

PCVX

PDYPY

PGNY

PINS

QTWO

SITE

SMCI

SNPS

SOFI

SONO

STEP

SWTX

TCKRF

TECK

URBN

VRSK

XMHQ

XPRO

Press Releases

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

Natera Issues Statement on Guardant Health Litigation

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Comments

Natera

뉴스

에 대한 최신 뉴스 Natera (NASDAQ:NTRA) 주식

금요일, 11월 01, 2024

일요일, 8월 11, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌